Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

Aardvark Therapeutics will debut on Nasdaq at $16/share, to raise $94M for hunger-focused metabolic disease treatments. ARD-101 Phase 3 data expected early 2025.

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

There were only 36 biotech IPOs last year, compared with 68 in 2015 and a record 85 in 2014 – and a rebound was expected in 2017. Are biotech IPOs back in fashion? | pharmaphorum Skip to main ...

Maze has two kidney disease drugs currently in the clinical, and the biotech was able raise $140 million in IPO cash to support those programs and more in its pipeline. Maze’s shares now trade ...